PMID- 28887839
OWN - NLM
STAT- MEDLINE
DCOM- 20190415
LR  - 20190415
IS  - 1600-0625 (Electronic)
IS  - 0906-6705 (Linking)
VI  - 27
IP  - 4
DP  - 2018 Apr
TI  - Anti-inflammatory effect of astaxanthin in phthalic anhydride-induced atopic 
      dermatitis animal model.
PG  - 378-385
LID - 10.1111/exd.13437 [doi]
AB  - In this study, we investigated anti-dermatitic effects of astaxanthin (AST) in 
      phthalic anhydride (PA)-induced atopic dermatitis (AD) animal model as well as in 
      vitro model. AD-like lesion was induced by the topical application of 5% PA to 
      the dorsal skin or ear of Hos:HR-1 mouse. After AD induction, 100 muL of 1 mg/mL 
      and 2 mg/mL of AST (10 mug or 20 mug/cm(2) ) was spread on the dorsum of ear or 
      back skin three times a week for four weeks. We evaluated dermatitis severity, 
      histopathological changes and changes in protein expression by Western blotting 
      for inducible nitric oxide synthase (iNOS), cyclooxygenase-2 (COX-2) and nuclear 
      factor-kappaB (NF-kappaB) activity. We also measured tumor necrosis factor-alpha (TNF-alpha), 
      interleukin-1beta (IL-1beta), interleukin-6 (IL-6) and immunoglobulin E (IgE) 
      concentration in the blood of AD mice by enzyme-linked immunosorbent assay 
      (ELISA). AST treatment attenuated the development of PA-induced AD. Histological 
      analysis showed that AST inhibited hyperkeratosis, mast cells and infiltration of 
      inflammatory cells. AST treatment inhibited expression of iNOS and COX-2, and 
      NF-kappaB activity as well as release of TNF-alpha, IL-1beta, IL-6 and IgE. In addition, AST 
      (5, 10 and 20 muM) potently inhibited lipopolysaccharide (LPS) (1 mug/mL)-induced 
      nitric oxide (NO) production, expression of iNOS and COX-2 and NF-kappaB DNA binding 
      activities in RAW 264.7 macrophage cells. Our data demonstrated that AST could be 
      a promising agent for AD by inhibition of NF-kappaB signalling.
CI  - (c) 2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
FAU - Park, Ju Ho
AU  - Park JH
AD  - College of Pharmacy and Medical Research Center, Chungbuk National University, 
      Cheongju, Chungbuk, Republic of Korea.
AD  - INIST ST CO., LTD., Eumseong-gun, Chungcheongbuk-do, Republic of Korea.
FAU - Yeo, In Jun
AU  - Yeo IJ
AD  - College of Pharmacy and Medical Research Center, Chungbuk National University, 
      Cheongju, Chungbuk, Republic of Korea.
FAU - Han, Ji Hye
AU  - Han JH
AD  - College of Pharmacy and Medical Research Center, Chungbuk National University, 
      Cheongju, Chungbuk, Republic of Korea.
FAU - Suh, Jeong Won
AU  - Suh JW
AD  - GDE Ltd., Siheung-si, Gyeonggi-do, Republic of Korea.
FAU - Lee, Hee Pom
AU  - Lee HP
AD  - College of Pharmacy and Medical Research Center, Chungbuk National University, 
      Cheongju, Chungbuk, Republic of Korea.
FAU - Hong, Jin Tae
AU  - Hong JT
AUID- ORCID: 0000-0002-6534-9575
AD  - College of Pharmacy and Medical Research Center, Chungbuk National University, 
      Cheongju, Chungbuk, Republic of Korea.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Denmark
TA  - Exp Dermatol
JT  - Experimental dermatology
JID - 9301549
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (IL1B protein, mouse)
RN  - 0 (Interleukin-1beta)
RN  - 0 (Interleukin-6)
RN  - 0 (Lipopolysaccharides)
RN  - 0 (NF-kappa B)
RN  - 0 (Phthalic Anhydrides)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 0 (Xanthophylls)
RN  - 0 (interleukin-6, mouse)
RN  - 37341-29-0 (Immunoglobulin E)
RN  - 8XPW32PR7I (astaxanthine)
RN  - EC 1.14.13.39 (Nitric Oxide Synthase)
RN  - EC 1.14.99.1 (Cyclooxygenase 2)
RN  - UVL263I5BJ (phthalic anhydride)
SB  - IM
MH  - Administration, Cutaneous
MH  - Animals
MH  - Anti-Inflammatory Agents/pharmacology/*therapeutic use
MH  - Cell Count
MH  - Cyclooxygenase 2/metabolism
MH  - Dermatitis, Atopic/chemically induced/*drug therapy/*metabolism/pathology
MH  - Disease Models, Animal
MH  - Immunoglobulin E/blood
MH  - Interleukin-1beta/blood
MH  - Interleukin-6/blood
MH  - Lipopolysaccharides/pharmacology
MH  - Lymph Nodes/pathology
MH  - Mast Cells
MH  - Mice
MH  - NF-kappa B/*metabolism
MH  - Nitric Oxide Synthase/metabolism
MH  - Organ Size
MH  - Phthalic Anhydrides
MH  - RAW 264.7 Cells
MH  - Severity of Illness Index
MH  - Signal Transduction/*drug effects
MH  - Tumor Necrosis Factor-alpha/blood
MH  - Xanthophylls/pharmacology/therapeutic use
OTO - NOTNLM
OT  - IgE
OT  - NF-kappaB
OT  - astaxanthin
OT  - atopic dermatitis
OT  - cytokine
OT  - skin inflammation
EDAT- 2017/09/10 06:00
MHDA- 2019/04/16 06:00
CRDT- 2017/09/10 06:00
PHST- 2017/08/29 00:00 [accepted]
PHST- 2017/09/10 06:00 [pubmed]
PHST- 2019/04/16 06:00 [medline]
PHST- 2017/09/10 06:00 [entrez]
AID - 10.1111/exd.13437 [doi]
PST - ppublish
SO  - Exp Dermatol. 2018 Apr;27(4):378-385. doi: 10.1111/exd.13437.